A pediatric bone marrow transplant (BMT) replaces a child’s diseased or failing blood-forming system with healthy stem cells, either from a donor or, less often, from the child’s own stored cells. It is used for high-risk childhood leukemias, marrow failure syndromes such as severe aplastic anemia and Fanconi anemia, inherited immune deficiencies, hemoglobin disorders, and certain metabolic diseases. For the clinician, success depends on choosing the right indication, the right donor, the right conditioning, and anticipating complications that differ in important ways from adult transplantation.
What Is a Pediatric Bone Marrow Transplant?
Bone marrow is the soft tissue inside bones that produces red cells, white cells, and platelets. Its composition and function rest on a small population of hematopoietic stem cells that can both renew themselves and generate every blood lineage. A transplant works by giving the child a new supply of these cells.
Although the term “bone marrow transplant” persists, stem cells can be collected from marrow, mobilized peripheral blood, or umbilical cord blood. The distinction is explained in more detail in our comparison of bone marrow transplant vs stem cell transplant. In children, marrow and cord blood are used more often than in adults, partly because of their lower rates of chronic graft-versus-host disease.
The healthy donor marrow cells travel to the recipient’s marrow after an intravenous infusion, a process called engraftment, and begin producing blood cells within weeks.
Indications in Children
Pediatric indications span malignant and non-malignant blood disorders, and the non-malignant share is larger than in adult practice.
| Category | Examples | Usual transplant type |
|---|---|---|
| Malignant | High-risk or relapsed acute lymphoblastic leukemia, acute myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome | Allogeneic |
| Solid tumors | High-risk neuroblastoma, some relapsed lymphomas | Autologous |
| Marrow failure | Severe aplastic anemia, Fanconi anemia, Diamond-Blackfan anemia | Allogeneic |
| Hemoglobin disorders | Sickle cell disease, transfusion-dependent thalassemia | Allogeneic |
| Immune deficiencies | Severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome, chronic granulomatous disease | Allogeneic |
| Metabolic disorders | Hurler syndrome, some leukodystrophies | Allogeneic |
Inherited conditions matter for donor choice. Fanconi anemia, for example, causes progressive bone marrow failure and a raised risk of leukemia, and siblings must be tested to make sure a potential donor does not carry the same disorder.
Clinical Presentation Before Referral
Children who eventually need a transplant usually come to attention through signs of marrow dysfunction. Recurrent or unusual infections reflect low or abnormal white cells. Pallor and tiredness reflect anemia. Bruising, nosebleeds, and petechiae reflect low platelet counts.
Other patterns point to specific diagnoses. Leukemia may present with fever, bone pain, and enlarged lymph nodes, liver, or spleen. Fanconi anemia may be suspected from short stature, thumb or forearm anomalies, or skin pigment changes. Metabolic disorders may show developmental delay, coarse features, or organ enlargement, and SCID often appears in infancy with severe infections and failure to thrive.
Pre-Transplant Evaluation and Donor Selection
Confirming the Diagnosis
The workup typically includes a complete blood count, bone marrow aspirate and biopsy, cytogenetics, and molecular testing. In suspected inherited marrow failure, chromosomal breakage testing for Fanconi anemia and targeted gene panels help secure the diagnosis before a donor is chosen.
Assessing Fitness
Organ function is checked with kidney and liver tests, echocardiogram, pulmonary function tests in older children, and dental review. Infectious disease screening, including viral serologies, guides prevention after transplant. Fertility preservation should be discussed with families where feasible.
Choosing a Donor
Donors are matched by human leukocyte antigen (HLA) typing. A fully matched sibling is traditionally preferred. When none is available, options include a matched unrelated donor from a registry, umbilical cord blood, or a haploidentical (half-matched) parent or sibling. Haploidentical transplants have widened access because nearly every child has a parent who is a half match.
The Transplant Process and Treatment Strategies
Conditioning
Conditioning is the chemotherapy, sometimes with radiation or antibody therapy, given before the infusion. In malignant disease it aims to eradicate residual cancer; in non-malignant disease it mainly suppresses the immune system so the graft is not rejected. Children with Fanconi anemia are highly sensitive to DNA-damaging agents, so they receive reduced-intensity regimens. Total body irradiation is used cautiously in young children because of effects on growth and development.
Allogeneic vs Autologous
An allogeneic transplant uses donor cells and offers a graft-versus-leukemia effect, where donor immune cells attack residual cancer. An autologous transplant uses the child’s own collected cells as a rescue after very high-dose chemotherapy, as in high-risk neuroblastoma, and carries no risk of GVHD.
Typical Timeline
| Phase | Approximate timing | Main focus |
|---|---|---|
| Conditioning | About 1 week before infusion | Chemotherapy, with or without radiation |
| Day 0 | Infusion day | Stem cells given through a central line |
| Neutropenic phase | First 2 to 4 weeks | Infection prevention, transfusions, mucositis care |
| Engraftment | Often 2 to 4 weeks; later with cord blood | Rising neutrophil and platelet counts |
| Early recovery | Up to about day 100 | Watching for acute GVHD, viral reactivation |
| Long-term follow-up | Beyond the first year | Immune recovery, revaccination, late effects |
Complications and Post-Transplant Care
Graft-versus-host disease (GVHD) occurs when donor immune cells attack the recipient’s tissues, most often the skin, gut, and liver. Prophylaxis usually combines drugs such as calcineurin inhibitors with methotrexate or other agents. Acute GVHD is treated first with corticosteroids.
Other major risks include bacterial, fungal, and viral infections, especially cytomegalovirus and adenovirus; veno-occlusive disease of the liver; graft failure; and relapse of the original disease. Children also face distinctive late effects: growth impairment, thyroid and pubertal problems, infertility, cataracts, learning difficulties, and a risk of second cancers. Structured survivorship clinics monitor these for years, and childhood vaccines are repeated once the immune system recovers.
Newer directions, including gene therapy for some inherited disorders and graft engineering that removes specific T-cell subsets, are expanding the options described in our bone marrow guide.
Key Takeaways
- Pediatric BMT treats high-risk cancers and a wider range of non-malignant disorders than adult practice.
- Donor choice rests on HLA matching; haploidentical and cord blood options mean most children can find a donor.
- Conditioning must be tailored to diagnosis, age, and inherited DNA-repair defects.
- GVHD, infection, and late effects on growth, fertility, and development require long-term follow-up.
Frequently Asked Questions
How long does a child stay in hospital after a bone marrow transplant?
Most children remain in hospital for several weeks, until their counts recover and they can eat, drink, and take medicines by mouth. Close outpatient follow-up continues for roughly the first 100 days, often with frequent clinic visits.
Can a parent be a donor for their child?
Yes. A parent is almost always a half match, making haploidentical transplant possible. Special techniques to reduce GVHD, such as post-transplant cyclophosphamide or graft manipulation, are used to make these transplants safer.
Is the donation procedure painful for a sibling donor?
Marrow harvest is done under general anesthesia, so the child donor feels no pain during collection. Afterwards there may be soreness at the hip for a few days, and donor safety is reviewed by a team independent of the recipient’s care.
What are the long-term effects of pediatric BMT?
Possible late effects include slowed growth, hormone and thyroid problems, delayed puberty, infertility, cataracts, heart or lung effects, and second cancers. Risk depends heavily on the conditioning used, which is why lifelong survivorship follow-up is recommended.
